Related Experiment Video

Updated: Nov 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.0K

The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review

Qinchao Wu1, Baochen Bai1, Chao Tian1

  • 1Department of Cardiology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, 266100, Shandong, China.

Cardiovascular Drugs and Therapy
|April 13, 2021
PubMed
Abstract

Insights

Novel targeted cancer drugs improve survival but can cause heart problems. Understanding cardiotoxicity from targeted therapies like HER2 and VEGF inhibitors is crucial for patient safety.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Targeted cancer therapies have improved survival rates.
  • These novel drugs, including HER2 and angiogenesis inhibitors, can cause significant cardiac side effects.
  • Current guidelines for managing cardiotoxicity are insufficient, necessitating further research.

Purpose of the Study:

  • To review targeted therapies associated with cardiotoxicity.
  • To update knowledge on the clinical evidence, molecular mechanisms, and management of cardiotoxicity.
  • To highlight the importance of understanding cardiotoxicity for optimizing targeted cancer treatment.

Main Methods:

  • Literature review of targeted therapies and their cardiotoxic effects.
  • Analysis of clinical evidence and molecular mechanisms.
  • Examination of current management strategies and guidelines.

Main Results:

  • Several targeted therapies, including HER2 inhibitors (e.g., trastuzumab) and VEGF inhibitors, are associated with cardiotoxicity.
  • Mechanisms of cardiotoxicity differ from traditional chemotherapy.
  • Clinical manifestations include heart failure, hypertension, thrombosis, and arrhythmias.

Conclusions:

  • Improved understanding of cardiotoxicity is essential for managing patients on targeted therapies.
  • Further clinical trials and experimental studies are needed to refine management strategies.
  • Cardioprotective strategies may be beneficial for patients receiving targeted agents.
Keywords:
Angiogenesis inhibitorsCardiotoxicityTargeted drugsTrastuzumabTyrosine kinase inhibitors

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.4K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.0K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.3K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
650
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
160